Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL11381767 | 0.96 | SMN1; SMN2 (0.59) | ADORA2BLMNAMAPTSMN1; SMN2ADORA2A | |
| SCHEMBL11380544 | 0.89 | ADORA2B (0.59) | ADORA2BLMNAMAPTSMN1; SMN2ADORA2A | |
| SCHEMBL7456005 | 0.87 | ADORA2B (0.55) | ADORA2BLMNAMAPTADORA2APOLB | |
| SCHEMBL19036787 | 0.87 | ADORA2B (0.69) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 | |
| SCHEMBL14507747 | 0.86 | ADORA2A (0.64) | ADORA2BLMNAMAPTADORA2A | |
| SCHEMBL11377411 | 0.86 | ADORA2B (0.59) | ADORA2BLMNAMAPTADORA2ARXFP1 | |
| SCHEMBL13659055 | 0.85 | SMN1; SMN2 (0.66) | ADORA2BLMNAMAPTSMN1; SMN2ADORA2A | |
| SCHEMBL14507751 | 0.84 | PDE4A (0.61) | ADORA2BLMNAMAPTSMN1; SMN2ADORA2A | |
| SCHEMBL14507748 | 0.84 | PDE4A (0.58) | ADORA2BLMNAMAPTADORA2APOLB | |
| SCHEMBL19036507 | 0.84 | ADORA2B (0.68) | ADORA2BLMNAMAPTSMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4061753-A | Treating psoriasis with transient pro-drug forms of xanthine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-12-06 | — | — | US | claimed |
| US-20070105878-A1 | Purine formulations and methods for managing disorders | REAUME ANDREW | 2007-05-10 | — | — | US | disclosed |
| US-20070105878-A1 | Purine formulations and methods for managing disorders | REAUME ANDREW | 2007-05-10 | — | — | US | disclosed |
| WO-2007041506-A1 | PURINE FORMULATIONS AND METHODS FOR MANAGING DISORDERS | MELIOR DISCOVERY, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-4275064-A | Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| US-4061753-A | Treating psoriasis with transient pro-drug forms of xanthine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105878-A1 | Purine formulations and methods for managing disorders | TPMT, UMPS, SLC10A2 | ADORA2B 38/4885LMNA 2994/4885MAPT 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.